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Abstract
Elevated aerobic glycolysis in cancer cells (the Warburg effect) may be attributed to respiration injury or mitochondrial
dysfunction, but the underlying mechanisms and therapeutic significance remain elusive. Here we report that induction of
mitochondrial respiratory defect by tetracycline-controlled expression of a dominant negative form of DNA polymerase c
causes a metabolic shift from oxidative phosphorylation to glycolysis and increases ROS generation. We show that
upregulation of NOX is critical to support the elevated glycolysis by providing additional NAD+. The upregulation of NOX is
also consistently observed in cancer cells with compromised mitochondria due to the activation of oncogenic Ras or loss of
p53, and in primary pancreatic cancer tissues. Suppression of NOX by chemical inhibition or genetic knockdown of gene
expression selectively impacts cancer cells with mitochondrial dysfunction, leading to a decrease in cellular glycolysis, a loss
of cell viability, and inhibition of cancer growth in vivo. Our study reveals a previously unrecognized function of NOX in
cancer metabolism and suggests that NOX is a potential novel target for cancer treatment.
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Introduction
Development of selective anticancer agents based on the
biological differences between normal and cancer cells is essential
to improve therapeutic selectivity. Increased aerobic glycolysis and
elevated oxidative stress are two prominent biochemical features
frequently observed in cancer cells. A metabolic shift from
oxidative phosphorylation in the mitochondria to glycolysis in
the cytosol in cancer was first described some 80 years ago by Otto
Warburg, who later considered such metabolic changes as ‘‘the
origin of cancer’’ resulting from mitochondrial respiration injury
[1]. It is now recognized that elevated glycolysis is a characteristic
metabolism in many cancer cells. In fact, active glucose uptake by
cancer cells constitutes the basis for fluorodeoxyglucose-positron
emission tomography (FDG-PET), an imaging technology com-
monly used in cancer diagnosis. In addition, cancer cells exhibit
elevated generation of reactive oxygen species (ROS), which
disturb redox balance leading to oxidative stress [2]. However,
despite these long-standing observations and clinical relevance, the
biochemical/molecular mechanisms responsible for such meta-
bolic alterations and their relationship with mitochondrial
respiratory dysfunction remain elusive. Identification of the major
molecular players involved in the metabolic switch in the context
of mitochondrial dysfunction in cancer cells is important for
understanding the underlying mechanisms and developing more
effective treatment strategies.
For many years, studies of mitochondrial respiratory defect
usually involve the use of ru cells, in which mitochondrial DNA
(mtDNA) deletion is generated by chronic exposure of cells to the
DNA-intercalating agent ethidium bromide [3]. While successful,
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the use of ru cells generated by this method as a model for
metabolic study has potential complications due to possible
nuclear DNA damage by ethidium bromide and thus may
compromise data interpretation [4]. To investigate the relation-
ship between mitochondrial dysfunction and alterations of cellular
metabolism, it is important to establish a model system in which
the mitochondrial function can be regulated without significant
impact on the nuclear genome. Mitochondrion DNA polymerase
gamma (POLG) is a key enzyme responsible for the replication of
mtDNA [5,6], which encodes for 13 critical components of the
respiratory chain. Thus, it is possible to specifically impact the
mitochondrial respiratory function by selectively suppressing
POLG, which is not involved in nuclear DNA replication. Indeed,
a dominant negative form of POLG (POLGdn), which contains a
point mutation (D1135A) in the coding sequence, has been
previously identified and demonstrated to have a negative impact
on mtDNA replication, causing respiratory defect after transfec-
tion [7,8]. Thus, it is possible to use a gene transfection strategy to
selectively impact mitochondrial function without affecting nuclear
DNA.
NOX are a group of membrane-associated enzymes capable of
oxidizing NADPH or NADH to NADP+ or NAD+, leading to
generation of superoxide by one-electron reduction of oxygen [9].
There are seven members of the NOX family in the human
genome with unique patterns of cellular expression and conserved
structure. They include NOX1 (also called Mox1), NOX2
(gp91phox), NOX3, NOX4, NOX5, and the dual oxidases
DUOX1 and DUOX2. Activation of most NOX complexes
requires proper assembling of multiple protein components,
including p22phox (CYBA), Rac-GTPase (Rac1 and Rac2),
p47phox, p67phox, p40phox, NOX organizer 1 (NOXO1), and
NOX activator 1 (NOXA1) [10,11]. NOX enzymes have been
implicated in host defense, regulation of gene expression, ROS
generation, and redox signaling [12]. In many cancers, NOX
activities are increased and mRNAs are overexpressed [13–16],
but the precise functions of NOX in cancer cell metabolism
remain unclear.
In the current study, we adapted the molecular strategy using
POLGdn to generate a tetracycline-inducible cell system as
previously described [8] and used this model system and cancer
cells with compromised mitochondrial respiration to investigate
the relationship between mitochondrial respiratory dysfunction
and metabolic alterations and to identify the key molecular players
in the metabolic switch from oxidative phosphorylation to aerobic
glycolysis. We discovered an unexpected metabolic function of
NOX, which is important for maintaining high glycolytic activity
in cells with mitochondrial respiratory dysfunction. We also found
that cancer cells with mitochondrial dysfunction due to the
expression of oncogenic Ras or a loss of p53 consistently exhibited
elevation in NOX activity and were highly sensitive to NOX
suppression. Importantly, the significant increase in the expression
of p22phox, a main component of NOX complex, was found in
human pancreatic carcinoma, where K-Ras aberrant activation is
prevalent. Furthermore, suppression of NOX exhibited significant
antitumor activity in vivo, suggesting that NOX can be a potential
target for cancer therapy.
Results
POLGdn Expression Leads to Mitochondrial Dysfunction
and Elevated Glycolysis
To investigate the relationship between mitochondrial dysfunc-
tion and metabolic changes, we first established an experimental
cell model where the mitochondrial respiratory status can be
regulated via a tetracycline-inducible system. This model is based
on the fact that mtDNA replication is catalyzed by DNA
polymerase c (POLG) and that POLGdn can abolish mtDNA
replication leading to respiration defects [7,17]. A 4-kb DNA
fragment containing the full-length POLGdn gene with a D1135A
mutation was constructed into a mammalian expression vector
pcDNA4/TO (Figure 1A), which was then transfected into human
T-Rex 293 cells to generate a Tet/on inducible system as
described in the Materials and Methods. As shown in Figure 1B,
in the absence of doxycycline (Tet/off), the endogenous POLG
was readily detected by POLG antibody, but the expression of
exogenous POLGdn was not detectable (absence of the FLAG
signal), suggesting that this experimental system was tightly
controlled without detectable leakage. Addition of doxycycline
(Tet/on) to the culture medium induced the expression of
POLGdn (detected by anti-FLAG), which remained expressed
for over 2 wk in the presence of doxycycline. The induced
expression of POLGdn was also evident by the increase of the
band intensity detected by anti-POLG antibody (Figure 1B).
The expression of POLGdn led to a severe decrease of mtDNA
synthesis, as evidenced by a dramatic decrease of mtDNA 2 d after
doxycycline induction (Figure 1C). To determine the mtDNA-
encoded gene expression, Northern blot analysis was used to
measure the level of mtDNA-encoded cytochrome c oxidase
subunit II (COII) RNA. Figure 1D showed that the expression of
COII RNA was decreased on day 2, almost depleted on day 6, and
disappeared by day 10 after POLGdn induction. Western blot
analysis showed a corresponding depletion of COII protein in a
time-dependent manner (Figure 1E).
To evaluate the metabolic alterations subsequent to POLGdn
induction, we first measured cellular oxygen consumption as an
indicator of mitochondrial respiratory capacity [18]. Expression of
POLGdn caused a time-dependent decrease in oxygen consump-
tion, detectable on day 2 and dramatically decreased on day 6
(Figure 2A). Associated with this decrease in mitochondrial
respiration, the Tet/on cells became highly glycolytic, as
evidenced by a significant increase in glucose uptake (Figure 2B)
Author Summary
Glycolysis is a cytoplasmic metabolic process that produc-
es energy from glucose. In normal cells, the rate of
glycolysis is low, and glycolysis products are further
processed in the mitochondria via oxidative phosphoryla-
tion, a very efficient energy-producing process. Cancer
cells, however, display higher levels of glycolysis followed
by cytoplasmic fermentation, and reduced levels of
oxidative phosphorylation. It was thought that increased
glycolysis is associated with mitochondrial dysfunction,
but how these phenomena are functionally linked was not
known. Understanding how these processes are regulated
will be essential for developing more effective anti-cancer
therapies. Here, we show that induction of mitochondrial
dysfunction by either genetic or chemical approaches
results in a switch from oxidative phosphorylation to
glycolysis. We further show that NADPH oxidase (NOX), an
enzyme known to catalyze the oxidation of NAD(P)H, also
plays a critical role in supporting increased glycolysis in
cancer cells by generating NAD+, a substrate for one of the
key glycolytic reactions. Inhibition of NOX leads to
inhibition of cancer cell proliferation in vitro and suppres-
sion of tumor growth in vivo. This study reveals a novel
function for NOX in cancer metabolism, explains the
increased glycolysis observed in cancer cells, and identifies
NOX as a potential anti-cancer therapeutic target.
Role of NOX in Cancer Metabolism
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Figure 1. POLGdn expression led to the depletion of mtDNA-encoded respiratory chain components. (A) POLGdn-pcDNA4/TO construct
and nucleotide sequencing analysis confirming the D1135A mutation. (B) Induction of POLGdn expression by doxycycline. T-Rex293 cells carrying
POLGdn construction were incubated with doxycycline at an indicated time point. POLGdn expression was detected by anti-FLAG antibody, while
both the endogenous POLG and POLGdn proteins were detected by anti-POLG antibody using Western blot assay. (C) Dramatic decrease of mtDNA
by expression of POLGdn. Southern blot assay was used to measure mtDNA content. 10 mg total cellular DNA (including genomic DNA and mtDNA)
from each sample was digested with SphI to linealize the circular mtDNA, followed by gel electrophoresis. 32P-labeled mitochondrial COII DNA
fragment was used as a probe to detect mtDNA. (D) Assay of mtDNA-encoded COII RNA expression by northern blot analysis. (E) Detection of
mitochondrial DNA-encoded COII protein by Western blot assay.
doi:10.1371/journal.pbio.1001326.g001
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Figure 2. Suppression of mitochondrial respiration by POLGdn expression led to an elevation of glycolysis. (A) Time-dependent
decrease in cellular oxygen consumption following POLGdn expression. Reduction of oxygen consumption was observed as early as 2 d after
POLGdn expression, and the cells dramatically decreased their ability to consume oxygen with prolonged POLGdn expression. (B) Increased glucose
uptake in POLGdn-expressing cells (Tet/on, d12). Cells (26106) were incubated in 5 ml glucose-free RPMI1640 medium for 2 h, followed by
incubation with 0.2 mCi/mL 3H-2-deoxyglucose for 1 h. Cellular uptake of 3H-2-deoxyglucose was determined by liquid scintillation counting after the
cells were washed two times with PBS. Error bars, 6SD. p,0.01 (n= 3). (C) Increased lactate generation in Tet/on cells. Lactate in Tet/off and Tet/on
(day 12) cells was measured at the indicated time points after changing to fresh culture medium. (D) Increased protein level of hexokinase II (HKII)
following POLGdn expression. Upper panels show representative HKII protein by Western blotting assay at the indicated days after POLGdn induction
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and elevated production of lactate, a metabolic product of
glycolysis (Figure 2C). Consistent with the active glycolysis, the
Tet/on cells showed an upregulation of hexokinase II (HKII), a
rate-limiting enzyme of the glycolytic pathway (Figure 2D). This
increase in glycolysis seemed effective in compensating the
decrease of ATP production in the mitochondria, since the overall
cellular ATP levels only decreased moderately (Figure 2E), even on
day 12 when respiration was severely suppressed.
Since the mitochondrial respiratory chain is a major site of
cellular ROS generation, we examined if induction of mitochon-
drial dysfunction by POLGdn could lead to a change in cellular
ROS. Flow cytometry analysis of cells stained with hydroethidine
(HET), a relatively specific chemical probe for superoxide (O2
2)
[19] showed that the cellular O2
2 level was significantly decreased
in the Tet/on cells at day 12 (Figure 3A). Consistently, MitoSox
Red, a mitochondrial O2
2 indicator, revealed a significant
decrease in mitochondrial O2
2 in the Tet/on cells (Figure 3B).
In contrast, a general redox-sensitive probe DCF-DA, which
detects cellular H2O2 and other ROS, revealed a significant
increase in cellular ROS in the Tet/on cells (Figure 3C).
Because O2
2 can be converted to H2O2 by the mitochondrial
superoxide dismutases (SOD2) or the cytosolic SOD1, we tested
the possibility that the increase in cellular H2O2 and the decrease
in O2
2 observed in the Tet/on cells might be a consequence of
altered SOD activity. Western blot analysis showed that the
mitochondrial SOD2 remained unchanged (Figure 3D), whereas
the basal expression of cytosolic SOD1 was abundant in the Tet/
off cells and was further increased by day 4 after POLGdn
induction (Figure 3E). Concurrently, SOD1 activity was also
increased (Figure 3F). Taken together, these data suggest that the
increase in cellular ROS detected by DCF-DA was most likely due
to elevated generation of O2
2 outside the mitochondria, and such
cytosolic O2
2 was then converted to H2O2 by the elevated SOD1.
Upregulation of NOX Is Important to Maintain High
Glycolytic Activity in Cells with Mitochondrial
Dysfunction
Since NOX is a membrane-associated enzyme capable of
generating ROS outside the mitochondria [20], we then measured
the membrane-associated NOX activity of the Tet/on cells in
comparison with Tet/off cells, using standard NOX assay
described previously [21,22]. The mitochondrial respiratory
defective cells consistently exhibited a significant increase in
NOX activity, which was detected 2 d after POLGdn induction
and remained high as long as the cells were maintained in Tet/on
stage (Figure 4A). This increase in NOX activity was inhibited by
10 mM diphenyleneiodonium (DPI), a known inhibitor of NOX
[23], to less than 10% of the original NOX activity (Figure 4B). In
contrast, pharmacologic inhibitors of other ROS-generating
molecules including NOS inhibitor Nv-nitro-L-arginine mrthyl
ester hydrochloride (L-NAME, 100 mM), the mitochondrial
respiratory chain complex I inhibitor rotenone (20 mM), and the
xanthine oxidase inhibitor oxypurinol (100 mM) showed no effect
on the NOX activity assay (Figure 4B). To determine if the
increased NOX activity was due to an increase in gene expression,
we used semi-quantitative RT-PCR to evaluate possible changes
in RNA expression of various NOX components and showed that
the mRNA levels of NOX1, NOXA1, and p47phox were
significantly increased (Figure S1A–B, Text S1). Time-course
analysis of NOXA1 and p47phox expression showed that the
mRNA levels increased 2 d after Tet/on (Figure S1B), concurrent
with the timing of NOX activity increase. This elevated gene
expression was further quantitatively confirmed by qRT-PCR
assay (Figure 4C).
The elevated NOX in cells with mitochondrial dysfunction
induced by POLGdn suggests that NOX upregulation might be
functionally important for these cells. We then used DPI to test if
the POLGdn-expressing cells with mitochondrial respiratory
defects might be more vulnerable to NOX inhibition. As shown
in Figure 4D, the Tet/on cells were significantly more sensitive to
DPI treatment than the Tet/off cells, evident by a substantial loss
of mitochondrial integrity (ability to retain rhodamin-123), a
decrease in cell viability (annexin-V/PI double staining, Figure 4E),
and an inhibition of cell growth (Figure S1C). To test whether the
elevated NOX gene expression and NOX activity were only
limited to the POLGdn Tet/on system, we compared the
respiration defective (ru) cell line HL60-C6F (C6F cells) [24] with
its mitochondrial competent parental HL60 cell line and observed
that the mitochondrial respiration-defective C6F cells showed a
significant increase in NOX activity (Figure 4F) and elevated
expression of NOX1, NOXA1, and p47phox (Figure 4G).
Consistently, C6F cells were also more sensitive to DPI than the
parental HL60 cells (Figure 4H).
The above observations suggest that the up-regulation of NOX
might be important for the viability of cells with mitochondrial
dysfunction. Since respiration-defective cells are highly dependent
on glycolysis for cell survival, we tested the potential role of NOX
on glucose metabolism by evaluating the effect of NOX
knockdown on glucose uptake, ATP generation, and cellular
NAD+ level. siRNA was used to specifically knockdown the
expression of the critical NOX components NOX1 and p22phox
in both Tet/on and Tet/off cells (Figure S2A and S2B).
Interestingly, suppression of NOX by siRNA selectively impact
cells with mitochondrial dysfunction (Tet/on), evidenced by a
significant decrease in glucose uptake and reduced ATP genera-
tion, while cells with competent mitochondrial function (Tet/off
cells) were not affected (Figure 5A–B), suggesting a potential role of
NOX in glucose metabolism in cells that are highly glycolytic such
as in the cells with mitochondrial defect. We further measured
cellular NADH and NAD+ contents in the Tet/off and Tet/on
cells in the presence and absence of NOX inhibition. As shown in
Figure 5C, NADH and NAD+ were separated by HPLC and
eluted at 9 min and 15 min, respectively. The chemical identities
of NADH and NAD+ in these HPLC peaks were collected and
confirmed by mass spectrometry analysis (Figure S2C and S2D).
Quantitative analysis showed that the expression of POLGdn
(Tet/on) caused a decrease in NAD+ by approximately 30%
(75.5R53.6 ng/46106 cells; Figure 5D), indicating an increase in
NAD+ consumption by the high glycolytic activity when
mitochondrial respiration was suppressed by expression of
POLGdn. Inhibition of NOX by p22phox siRNA knockdown or
by DPI caused an additional 40%–50% decrease in NAD+, with a
corresponding increase in NADH (Figure 5D). Besides, cellular
NADP+/NADPH ratio was significantly increased in cells with
POLGdn expression (Figure 5E). The above data suggest that
NOX might by important to maintain high glycolytic activity in
by doxycycline. Lower panels show quantification of Western blot results using scanning and ImageJ software. Results are expressed as integrated
optical density. Each sample was normalized to b-actin content. Each bar represents the mean6 SEM of three independent experiments. * p,0.05; **
p,0.01. (E) Comparison of cellular ATP levels in cells with or without POLGdn expression. Cellular ATP contents in Tet/on cells (days 8 and 12) were
measured and compared with the Tet/off cells. Error bars, 6SD (** p,0.01 and n=3).
doi:10.1371/journal.pbio.1001326.g002
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Figure 3. Alterations in ROS generation and SOD expression in cells with mitochondrial defect induced by POLGdn. (A) Lower cellular
O2
2 in POLGdn-expressing cells (Tet/on, day 12). O2
2 was detected by flow cytometry using 200 ng/ml HET as fluorescent dye (p,0.001, Tet/off
versus Tet/on and n= 3). (B) Comparison of mitochondrial O2
2 in cells with POLGdn expression (Tet/on day 12) or without POLGdn (Tet/off).
Role of NOX in Cancer Metabolism
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the cells with mitochondrial defects by supplying additional NAD+
from oxidation of NADH. Indeed, the membrane-associated
NOX preparation was able to oxidize either NADPH or NADH
as the substrates, and the oxidase activity was decreased by
p22phox gene knockdown (Figure 5F). These data might explain
why p22phox knockdown could cause NAD+ level decrease in the
Tet/on cells.
Because NOX generates ROS, which might then stabilize HIF-
1a to stimulate glycolysis [25], we tested if altering NOX activity
would cause changes in ROS and HIF-1a. We knocked down
p22phox using siRNA and then induced POLGdn expression for
4 d. Cellular O2
2 and mitochondrial O2
2 levels did not show any
change on day 4 (Figure S2E–F), while knockdown p22phox
causes a detectable decrease in cellular H2O2 (Figure S2G),
consistent with the role of NOX in generating ROS outside the
mitochondria. HIF-1a was not induced in the POLGdn cells even
after 2 wk of Tet/on, while hypoxia induced a significant increase
of HIF-1a in the same cells (Figure 5G). These data together
suggest that induction of mitochondrial dysfunction did not
significantly change HIF-1a expression. Thus, HIF-1a seemed
not to play a major role in the POLGdn Tet/on cells to promote
glycolysis.
Cancer Cells with Compromised Mitochondrial Function
Due to p53 Loss Show Elevated NOX Activity and
Increased Sensitivity to NOX Inhibition
It is known that the tumor suppressor p53 plays an important
role in maintaining mitochondrial function through transcriptional
activation of SCO2 and the loss of p53 leads to a decrease in
mitochondrial respiration and increase in lactate generation
[26,27]. We reasoned that if NOX were important for the
survival of cells with mitochondrial respiratory defect, the p53-null
cells would be expected to have elevated NOX activity and be
sensitive to NOX inhibition. To test this possibility, we compared
NOX activity in human colon cancer cells (HCT116) with wild-
type p53 or p532/2. As shown in Figure 6A, the p532/2 cells had
a higher membrane-associated NOX activity. Further analysis by
semi-quantitative RT-PCR revealed that the expression of the
NOX components NOX1 and p67phox were increased in
HCT116 p532/2 cells (Figure S3A). Quantitative analysis using
qRT-PCR showed that NOX1 and p67phox in HCT116 p532/2
cells have about 2- and 4-folds increase in gene expression,
respectively, compared to HCT116 p53+/+ cells (Figure 6B).
To evaluate the importance of increased NOX for the survival
of HCT116 p532/2 cells, we tested their sensitivity to NOX
inhibitor DPI in comparison with the HCT116 p53+/+ cells. As
shown in Figure 6C, after DPI treatment for 24 h, HCT116
p532/2 cells exhibited a round-up morphology and detached,
leading to a decrease in the number of viable cells when compared
with HCT116 p53+/+ cells. To further confirm this different
sensitivity, the effect of DPI on mitochondrial transmembrane
potential was compared in both cell lines by flow cytometry using
rhodamin-123 staining. Substantially more HCT116 p532/2 cells
(32%) lost their mitochondrial transmembrane potential after DPI
treatment for 24 h, compared to 17% observed in the HCT116
p53+/+ cells (Figure 6D). These data suggest that NOX was up-
regulated in cancer cells with loss of p53 and that inhibition of
NOX could be a therapeutic strategy to preferentially kill these
cancer cells. Indeed, cell death measured by annexin-V/PI
analysis showed that the HCT116 p532/2 cells were more
vulnerable to DPI than the HCT116 p53+/+ cells (Figure S3B). To
further confirm that p532/2 cells have higher NOX activity,
H1299 cells were transfected with p53wt expression plasmid to
generate p53wt stably expressed H1299-p53wt cell line (Figure
S3C). We observed that forced expression of wild-type p53 in
H1299 cells have significantly decreased NOX activity (p,0.001)
(Figure S3D).
Upregulation of NOX in K-rasG12V-Expressing Cells and in
Pancreatic Cancer Specimens
Malignant transformation by oncogenic Ras is known to
attenuate mitochondrial function and promote glycolysis [28,29].
We introduced an inducible K-rasG12V expression vector into the
T-Rex 293 cells and observed that induction of K-rasG12V
expression caused a 50% decrease in mitochondrial respiration
[30]. Importantly, this also caused a significant increase in NOX
enzyme activity (Figure 7A) and elevated gene expression of the
NOX components (Figure S4A). In a separate experiment, stable
transformation of human pancreatic ductal epithelial (HPDE) cells
with K-rasG12V also induced NOX upregulation (Figure 7B and
Figure S4B). Western blot analysis of the K-rasG12V stably
transformed cells and two naturally occurring pancreatic cancer
cell lines (AsPC1 and Panc-1) showed that the protein level of
p22phox, an essential component of the NOX enzyme complex,
was substantially higher in pancreatic cancer cells than in non-
malignant HPDE cells (Figure 7C). Using the H-RasV12-trans-
formed human ovarian epithelial cell pair [31,32], we also found
that NOX activity in H-RasV12-transformed cells (T72Ras) was
significantly higher than that in their non-tumorigenic parental
T72 cells (Figure 7D). The increase in expression of NOX1, NOX2,
p22phox, and p47phox in the H-RasV12-transformed cells was
demonstrated by semi-quantitative RT-PCR analysis (Figure S4C)
and quantitatively confirmed by qRT-PCR (Figure 7E). To test if
the elevated NOX activity is important for the survival of the H-
RasV12-transformed cells, we compared the sensitivity of T72Ras
cells and the parental T72 cells to DPI. The transformed T72Ras
cells were more vulnerable to NOX inhibition by DPI, leading to a
substantial decrease of mitochondrial transmembrane potential
(Figure 7F).
To test the clinical relevance of the above observations, we
analyzed the expression of p22phox in clinical specimens using
primary pancreatic tissue microarrays containing 105 cases of
stage II pancreatic ductal carcinoma samples and 94 benign
pancreatic tissues (normal and pancreatitis tissues). As shown in
Figure 7G, about 48% (50/105) of the pancreatic cancer tissues
exhibited a high protein level of p22phox, whereas only about 7%
(7/94) of the benign pancreatic tissues were positive for p22phox.
These data suggest that p22phox was significantly higher in
pancreatic carcinoma than in non-malignant tissues (p,0.0001,
Fisher’s exact test).
Mitochondrial O2
2 was detected by flow cytometry using 5 mm MitoSox Red as fluorescent dye (p,0.001, Tet/off versus Tet/on and n= 3). (C)
Increase in cellular H2O2 level in POLGdn expressing Tet/on (day 12) cells. Cellular H2O2 was measured by flow cytometry using 4 mm DCF-DA as a
fluorescent dye (p,0.001, Tet/off versus Tet/on, and n= 3). (D) Protein level of mitochondrial superoxide dismutase (SOD2) in cells at the indicated
time points after POLGdn induction. SOD2 was assayed by Western blot analysis. b-actin was used as a loading control. (E) Protein level of cytosolic
superoxide dismutase (SOD1) in cells at the indicated time points after POLGdn induction. Left panels show representative Western blots, and right
panels show quantification of normalized SOD1 levels to b-actin controls from three independent experiments. Data are shown in mean 6 SEM.
* p,0.05. (F) Changes in SOD1 activity in cells at the indicated time points after POLGdn induction. Error bars, 6SD. *** p,0.001 (n=3).
doi:10.1371/journal.pbio.1001326.g003
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Figure 4. Cells with mitochondrial respiratory defects exhibit elevated NOX activity and are sensitive to NOX inhibition. (A) Increase
of membrane-associated NOX activity in cells with mitochondrial respiratory defects after induction of POLGdn expression (Tet/on, 2, 8, 12 d). Error
bars, 6SD. ** p,0.01 (n= 3). (B) Inhibition of NOX enzyme activity by DPI. The Tet/on cells (day 8) were treated with 10 mM DPI, 100 mM L-NAME,
20 mM rotenone, or 100 mM oxypurinol for 4 h, and the membrane-associated fractions were prepared for analysis of NOX activity. Error bars, 6SD.
*** p,0.001 (n= 3). (C) Increase in mRNA expression of NOX family members in Tet/on (day 2) cells, measured by qRT-PCR analysis. Error bars,6SD. **
p,0.01 (n=3). (D) Comparison of changes in mitochondrial transmembrane potential in Tet/off and Tet/on cells treated with DPI. Cells were pre-
induced by doxycycline for 7 d and then incubated with the indicated concentrations of DPI for 24 h. Mitochondrial transmembrane potential was
measured by flow cytometry using Rhodamine-123 as a potential-sensitive dye. Cells without DPI treatment were marked as control (Cont). (E) Cells
Role of NOX in Cancer Metabolism
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Suppression of NOX Exhibits Significant Inhibitory Effect
against Pancreatic Cancer in vivo
To test the role of NOX in cancer cell survival, we stably
knocked down p22phox expression in human pancreatic cancer
cells (Panc-1), using p22phox shRNA lentiviral particles (Santa
Cruz). The p22phox protein was substantially decreased and
NOX activity was significantly decreased (Figure 8A) in p22phox-
shRNA stably expressed cells compared with Panc-1 cells
transduced with the control shRNA lentiviral particals. The
knockdown of p22phox led to a significant decrease in cell growth
(Figure 8B) and colony formation capacity (Figure 8C). Suppres-
sion of NOX expression also significantly decreased glucose uptake
and lactate generation in pancreatic cancer cells (Figure 8D and
8E). To test the effect of NOX suppression on tumor growth in
vivo, we subcutaneously inoculated the Panc-1 cells bearing
p22phox-shRNA into the left flank of athymic nude mice (n=7)
and Panc-1 cells bearing control shRNA into the right flank of the
same 7 mice (56106 cells/injection site). Suppression of p22phox
expression significantly impaired tumor growth in vivo (Figure 8F
and 8G). The average tumor volume in the p22phox-shRNA
group was 53.4620.9 mm3, compared to 277.6677.8 mm3 in the
control group. After 60 d of cell inoculation, the average tumor
weight of the p22phox-shRNA xenografts was 1765 mg, com-
pared to 170662 mg in the control group (Figure 8H and 8I).
These data together suggest that NOX are essential for tumor
growth in vivo.
We then used DPI, a chemical inhibitor of NOX [23], to test its
potential therapeutic activity against pancreatic cancer in vivo.
Athymic nude mice were inoculated with Panc-1 cells subcutane-
ously (Text S1). When the tumor grew to 100 mm3, the mice were
divided into two groups for treatment with vehicle (PBS) as control
or with DPI (1.5 mg/kg mouse, i.v., 5 times/week). Such
treatment did not cause significant toxicity in the mice and there
was no loss of body weight in the DPI-treated group (Figure S5A).
The tumors grew progressively in the control group, whereas the
DPI-treated group exhibited significant retardation in tumor
growth (tumor volume 1,0686309.7 mm3 versus 139680.4 mm3,
Figure S5B). Some of the tumors in the treatment group showed
complete regression (Figure S5C). The average tumor weights of
the control group were significantly increased after about 10 wk
compared with the DPI-treated group (478698 mg versus
84652 mg, p,0.01, Figure S5D). These data suggest that DPI
could effectively inhibit pancreatic tumor growth without apparent
toxic side effects.
Discussion
In this study, we established a dominant-negative mitochondrial
DNA polymerase c inducible cell system, which enabled us to
investigate the relationship between mitochondrial respiratory
defect and metabolic alterations. Unlike ru cells derived by
chronic exposure of cells to ethidium bromide that could also
damage nuclear DNA, the POLGdn inducible cells provide a
clean isogenic model system that allowed the induction of
mitochondrial respiration suppression under well-defined condi-
tions without causing direct nuclear DNA damage. This model
made it possible to monitor metabolic alterations during the shift
from oxidative respiration to high glycolysis and to examine the
biochemical mechanisms in detail. The use of this cell system in
the current study led to a novel finding that NOX was consistently
up-regulated when mitochondrial respiration was suppressed by
the expression of POLGdn, and this was further confirmed in
cancer cells with loss of p53 or expression of oncogenic Ras.
Further study showed that such NOX elevation is critical for the
maintenance of high glycolytic activity in cells with mitochondrial
respiratory defects. This conclusion is supported by multiple lines
of evidence: (1) NOX expression and enzyme activity were
elevated in cells with different degrees of mitochondrial respiration
suppression induced by POLGdn, and in cancer cells with
mitochondrial defect due to a loss of p53, or under the stress of
Ras oncogenic signal. (2) In cells with mitochondrial respiratory
defect, a suppression of NOX led to a decrease in NAD+ level,
lower glucose uptake, and reduced ATP content, leading to loss of
cell viability. (3) Knockdown of NOX enzyme component
p22phox in Panc-1 cancer cells decreased glucose uptake and
lactate generation, decreased cancer cell proliferation and colony
formation capacity, and suppressed tumor growth in vivo.
Cells with mitochondrial respiration defect require a higher rate
of glycolysis, and activation of NOX seems necessary to provide
additional NAD+ to support the highly active glycolysis. Our study
showed that suppression of NOX in these cells caused a decrease
in NADH oxidation and lower cellular NAD+ level, a decrease in
glycolysis and cellular ATP, and a loss of cell viability. Thus, NOX
activation is important for providing additional NAD+ to support
active glycolysis. This is a previously unrecognized function of
NOX in energy metabolism. The production of NAD+ by lactate
dehydrogenase (LDH) is traditionally thought to be the main
pathway that maintains the supply of NAD+ for glycolysis. In
normal cells with competent mitochondria and a moderate level of
basal glycolytic activity, the NAD+ generated by LDH may be
sufficient to support the glycolytic reaction catalyzed by GAPDH.
However, in cells with mitochondrial dysfunction that require
higher glycolytic activity, upregulation of NOX seems important
to provide additional NAD+.
It is important to note that the POLGdn cells not only represent
a model system to study mitochondrial respiration defect as shown
in other ru cells, but it also allows us to investigate the metabolic
changes with various degrees of mitochondrial dysfunction. The
upregulation of NOX was observed not only at the stage when
mitochondrial respiration was severely inhibited by POLGdn
expressing, but we have also observed NOX activation in the early
stage (day 2 of Tet/on) of mitochondrial dysfunction. NOX
activation is also consistently observed in cancer cells with
mitochondrial dysfunction, such as HCT116 colon cancer cells
that lack p53 and thus have a disruption of cytochrome c oxidase
complex (complex IV) in the mitochondria [26]. Synthesis of
cytochrome c oxidase 2 (SCO2) is a transcriptional target of the
tumor suppressor p53. The alterations of metabolic parameters
including lactate generation and cellular ROS, NADH, and ATP
levels observed in the HCT116 SCO22/2 cell model [33] were
similar to those seen in the POLGdn-Tet/on cells in this study.
Interestingly, the Ras oncogene has recently been shown to cause
mitochondrial dysfunction by disrupting mitochondrial complex
activity [30,34], which is consistent with our findings in this study.
with mitochondrial respiratory defect (Tet/on, day 8) were more sensitive to DPI treatment (10 mM, 48 h) compared with the Tet/off cells. Cell viability
was measured by annexin-V/PI assay. (F) Increase of NOX activity in mDNA-less HL60-C6F (C6F) cells. Mean 6 SD. *** p,0.001 (n= 3). (G) Increase in
NOX family mRNA expression in C6F cells, measured by qRT-PCR assay. Data are shown as mean 6 SD of triplicate samples from two independent
experiments. * p,0.5; *** p,0.001. (H) C6F cells were more sensitive to DPI treatment. HL60 and its derived C6F cells were treated with indicated
concentration of DPI for 48 h. Cell viability was measured by annexin-V/PI assay.
doi:10.1371/journal.pbio.1001326.g004
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Figure 5. NOX supports glycolysis in cells with mitochondrial respiratory defects induced by POLGdn. (A) Inhibition of glucose uptake
by siRNA knockdown of NOX1 or p22phox in cells with mitochondrial respiratory defects (Tet/on, day 8), but not in cells with intact mitochondria
(Tet/off). p,0.05 (n= 3). Insert: Tet/off and Tet/on (at day 4) cells were transiently transfected with p22phox siRNA and the knockdown efficiency was
detected by anti-p22phox antibody using Western blot. Non-targeting control siRNA (Scram or sc) was used as negative control. (B) Effect of NOX1
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Stable transfection of human pancreatic ductal epithelial (HPDE)
cells by K-rasG12V, induced expression of K-rasG12V in T-Rex 293
Tet/on cells, or stable H-rasV12 transformation in human ovarian
epithelial cells led to a significant increase in NOX enzyme
activity. Moreover, the protein level of p22phox was found to be
significantly elevated in human primary pancreatic cancer tissues.
These observations together suggest that NOX up-regulation may
be an important cellular adaptive response to mitochondrial
dysfunction to enable the increase in glycolytic activity. As such,
NOX upregulation may be significant in many pathological
processes related to mitochondrial respiratory inhibition, especially
in cancer cells where mitochondrial respiratory dysfunction and
metabolic abnormalities are prominent.
The molecular mechanisms by which divergent triggers
including POLGdn, oncogenic Ras, and loss of p53 cause
upregulation of NOX remain unclear. In the study, we observed
that the expression of various NOX family members was
upregulated in cells with mitochondrial dysfunction. A recent
study suggests that SIRT1, a NAD+-dependent histone deacety-
lase, is involved in the negative regulation of NOX1 expression
[35]. It is possible that mitochondrial dysfunction induced by
various factors would lead to a decrease in cellular NAD+ content
due to active glycolysis that consumes NAD+, and therefore release
the SIRT1 suppression on NOX1 expression. Further study is
needed to investigate this possibility.
Conventionally, the membrane-bound NOX enzyme complex is
considered as ROS-generating machinery in phagocytes involved in
the defense against microorganisms and mediating certain inflam-
matory processes. Subsequently, nonphagocytic NOX family of
proteins homologous to gp91phox and other subunits have been
shown to generate ROS in nonphagocytic cells and have been
thought to contribute to various cancer cell proliferation and
progression [15,16,36,37]. Our study revealed an important function
of NOX in cellular energy metabolism, especially in cancer cells with
mitochondrial dysfunction. The ability of NOX inhibition to suppress
pancreatic cancer cell proliferation, to abrogate colony formation
ability, and to significantly suppress tumor growth in vivo suggests the
feasibility to target NOX for cancer treatment. Since pancreatic
cancer is highly resistant to many anticancer agents currently used in
clinic, targeting NOX may have significant clinical implications and
merit further investigation.
Materials and Methods
Generation of Mitochondrial Respiration-Defective Model
System
T-Rex 293 cells containing the pcDNA6/TR vector were
obtained from Invitrogen. Full-length POLGdn cDNA harboring
D1135A mutation and a FLAG-tag was excised by restriction
enzyme EcoRI digestion from the POLGdn plasmid described
previously [8]. The POLGdn fragment was subcloned into a
mammalian expression vector pcDNA4/TO (Invitrogen) at EcoRI
site and verified by nucleotide sequencing. The plasmid with
correct orientation was verified by HindIII or XhoI enzyme
digestion. The resulting POLGdn plasmid was then transfected
into T-Rex 293 cells using lipofectamine 2000 (Invitrogen) to
generate Tet/on inducible cell line. POLGdn positive colonies
were selected by Zeocin (250 mg/ml) for 15 d, and expression of
POLGdn was verified by 1 mg/ml doxycycline induction and
Western blot analysis using anti-FLAG antibody (Sigma).
Metabolic Measurements
Oxygen consumption, glucose uptake, and lactate generation
were described previously [18]. For measurement of oxygen
consumption, cells were trypsinized and resuspended in 1 ml fresh
culture medium pre-equilibrated with 21% oxygen at 37uC
followed by applying the cells to the sealed respiration chamber
of a Clark-type oxygen measuring system (Oxytherm, Hansatech
Instrument, Cambridge, United Kingdom) with constant stirring.
To measure cellular glucose uptake, cells in exponential growth
phase were washed with glucose-free medium and incubated in
fresh glucose-free RPMI 1640 medium for 3 h followed by an
incubation with 0.2 Ci/mL 3H-2-deoxyglucose for 1 h. The
glucose uptake represented by 3H radioactivity was determined
by liquid scintillation counting and normalized by cell number. To
measure lactate production, cells in 80% confluent were replen-
ished with fresh medium. Aliquots of the medium were removed at
the indicated time for measurement of lactate, using an Accutrend
lactate analyzer (Roche, Mannheim, Germany). At each time
point, cell number was also counted for normalization of lactate
generation. Cellular ATP contents were measured using CellTiter-
Glo Luminescent Cell Viability Assay kit (Promega) according to
manufacturer’s recommendations.
Flow Cytometry
Flow cytometry determination of ROS, mitochondrial mem-
brane potential, and cell death was performed using a BD
Biosciences FACSCalibur flow cytometer (Mountain View, CA)
and analyzed using the CellQuest software (Becton Dickinson).
Cellular superoxide level was measured by incubating cells with
200 ng/ml HET for 1 h and mitochondrial superoxide level was
measured by incubating the cells with 5 mm MitoSox Red for
60 min. Intracellular H2O2 contents were measured by incubating
cells with 4 mM DCF-DA at 37uC for 1 h and mitochondrial
transmembrane potential was assessed by incubating cells with
1 mM Rhodamine-123 (Rho-123) for 30 min before flow cytom-
eter analysis. Apoptosis was determined by using the annexin-V
and PI double staining method.
Assay for NAD(P)H Oxidase Activity and SOD1 Activity
NAD(P)H oxidase activity was measured by a lucigenin-derived
chemiluminescence assay as described [21,22]. Briefly, 5–7 mg
homogenized protein was incubated with its substrate 100 mM
NADH or NADPH in a phosphate buffer (50 mM, pH 7.0)
containing 150 mM NaCl and 1 mM EGTA for 15 min, followed
by an addition of 5 mM lucigenin for 15 min in dark. The
knockdown on ATP contents in cells with intact mitochondria (Tet/off) and cells with mitochondrial respiratory defect (Tet/on, day 8). p,0.01 (n= 4).
(C) HPLC analysis of cellular NAD+ and NADH levels. Standard NAD+ and NADH were used as references, which were monitored simultaneously at
260 nm and 340 nm, respectively. A lower NAD+ content was detected in the Tet/on cells with mitochondrial respiratory dysfunction and higher
glycolytic activity that consumed more of NAD+. Inhibition of NOX activity by p22phox siRNA and DPI resulted in further decrease in cellular NAD+
level. (D) Quantitation of intracellular NAD+ and NADH in triplicate experiments, using HPLC method as described above. (E) Effect of POLGdn
expression on cellular NADP+/NADPH ratio. *** p,0.001. (F) Knockdown of p22phox decreased NADPH/NADH oxidase activity. Comparing to the
control siRNA knockdown in Tet/on (d8) cells, p22phox knockdown significantly decreased cellular NADPH/NADH oxidase activity using either
NADHP or NADH as substrate. All error bars, 6SD. ** p,0.01; *** p,0.001 and n= 3. (G) HIF-1a is not stabilized following POLGdn induction. Protein
level of HIF-1a in cells at the indicated time points after POLGdn induction was assayed by Western blot analysis. Tet/off cells with 2% oxygen were
used as positive control. b-actin was used as a loading control.
doi:10.1371/journal.pbio.1001326.g005
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Figure 6. Cancer cells with loss of p53 and compromised mitochondrial respiration exhibit increased NOX and are sensitive to NOX
inhibition. (A) Comparison of membrane-associated NOX activity in human colon cancer HCT116 cells with wild-type p53 (p53+/+) or complete loss
of p53 (p532/2). Error bars, 6SD. * p,0.05 (n= 3). (B) Increased gene expression of NOX components NOX1 and p67phox in HCT116 p532/2 cells
detected by qRT-PCR assay. Error bars, 6SD. * p,0.05; ** p,0.01 (n= 3). (C) Comparison of cell morphology and cell growth in HCT116 p53+/+ and
HCT116 p532/2 cells treated with the NOX inhibitor DPI (10 mM, 24 h). (D) Inhibition of NOX by DPI (10 mM, 24 h) preferentially induced loss of
mitochondrial transmembrane potential in HCT116 p532/2 cells.
doi:10.1371/journal.pbio.1001326.g006
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Figure 7. Elevation of NOX in Ras transformed cells and in primary pancreatic cancer tissues. (A) Increase of NOX activity in T-Rex 293
Tet/on cells with 1 mo K-rasG12V induction compared with control. Error bars, 6SD. ** p,0.01 (n= 3). (B) NOX activity was substantially elevated in
pancreatic K-rasG12V stably transformed HPDE-kRasG12V cells compared with the parental HPDE (human pancreatic ductal epithelial) cells. Error bars,
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chemiluminescent signal (photon emission) was measured using a
Turner 20/20 luminometer (Turner Designs, Sunnyvale, CA). No
activity could be measured in the absence of NADH or NADPH.
Experiments were also performed with the following pharmaco-
logic inhibitors: a flavoprotein inhibitor DPI, a NOS inhibitor L-
NAME, a mitochondrial respiratory chain complex I inhibitor
rotenone, or a xanthine oxidase inhibitor oxypurinol.
Superoxide dismutase 1 (SOD1) activity was assayed using a
SOD assay kit (Cayman Chemicals) per the manufacturer’s
instructions. Briefly, cells were collected by centrifugation at
1,0006g for 10 min at 4uC, lysed, and centrifuged at 1,5006g for
5 min at 4uC. Cytosolic fraction containing SOD1 was obtained
from further centrifugation at 10,0006 g for 15 min.
NAD+ and NADH Measurement
Intracellular NAD+ and NADH were quantified by HPLC as
described previously [38] with some modifications. Briefly, after
trypsinization, 66106 cells were suspended in DMEM medium
without FBS and collected by centrifugation at 1,400 rpm for
5 min. Cells were then shock-frozen with liquid-nitrogen. The
cell pellets were resuspended in 150 ml extraction buffer
containing 7 volumes of ethanol and 3 volumes of 10 mM
potassium phosphate buffer, pH 8.5. The cells were disrupted
by sonication and then kept at room temperature for 30 min to
release cellular contents. Lysates were cleared by centrifugation
at 13,000 rpm at 4uC for 15 min. 100 ml of the supernatant
were subjected to HPLC analysis using an anion-exchange
column (Partisil-10 SAX, Whatman) at a flow rate of 1 ml/min
from 100% buffer A (5 mM NaH2PO4, pH 4.0) to 100% buffer
B (250 mM NAH2PO4+0.5 M NaCl, pH 4.75) over 20 min,
followed by another 5 min isocratic 100% buffer A. Pure NAD+
and NADH were used as reference standards and for
quantitative calibration. NAD+ and NADH were detected by
UV absorbance at 260 nm and 340 nm with retention times of
8.9 min and 15.4 min, respectively. The peaks corresponding
NAD+ and NADH were collected according to the standards’
retention time, freeze-dried in a lyophilizor, and further
confirmed by MALDI-MS analysis (Bruker Daltonics). In HPLC
analysis, the amount of cellular NAD+ and NADH of each
sample was quantified based on the peak area compared to the
standard curve generated by NAD+ and NADH standards.
Analysis of p22phox Expression in Pancreatic Tissues on
Microarray
Immunohistochemical staining for p22phox was performed
on 4-mm unstained sections from the tissue microarray blocks
consisting of 105 stage II pancreatic ductal carcinoma and
their paired non-neoplastic pancreatic tissue samples from
patients who underwent pancreaticoduodenetomy at our
institution. The use of clinical specimens for tissue array study
was approved by the Institutional Review Board of MD
Anderson Cancer Center. To retrieve the antigenicity, the
tissue sections were treated at 100uC in a steamer containing
10 mmol citrate buffer (pH, 6.0) for 60 min. The sections were
then immersed in methanol containing 0.3% hydrogen
peroxidase for 20 min to block the endogenous peroxidase
activity and were incubated in 2.5% blocking serum to reduce
nonspecific binding. The sections were then incubated with a
rabbit polyclonal antibody against p22phox (Santa Cruz, 1:100
dilution) at 4uC overnight, washed, and then incubated with
secondary antibody at room temperature for 60 min. Standard
avidin-biotin immunohistochemical analysis of the sections
was done according to the manufacturer’s recommendations
(Vector Laboratories, Burlingame, CA) and photographed
using a digital camera attached to the microscope. The
staining results were evaluated by a gastrointestinal patholo-
gist. Since all the pancreatic cancer samples showed either
negative or diffuse staining for p22phox, the levels of p22phox
expression were graded based on the staining intensity as
negative (0), weak (1), moderate (2), and strong (3). P22phox
expression was categorized as p22phox-low (intensity score of 0
or 1) or p22phox-high (intensity score of 2 or 3).
Assay of in vivo Antitumor Activity of NOX Inhibition by
p22phox-shRNA
The experiments with mouse xenografts were carried out
according to the protocols approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Texas
MD Anderson Cancer Center. Each side of the seven 10-wk-old
athymic nude mice received a subcutaneous injection of 56106
Panc-1 cells bearing p22phox-shRNA (p22phox-shRNA, left flank)
or control shRNA (c-shRNA, right flank). Tumor size and body
weight were measured throughout the experiment. Moribund
animals were sacrificed as mandated by the IACUC protocol, and
the tumor weight was recorded. Tumor volume was calculated
using the equation: tumor volume (mm3) =L * W *(L+W)/2 *
0.526.
Statistical Analyses
The Kolmogorov-Smirnov test (Cell Quest Pro software,
Becton-Dickinson, San Jose, CA, USA) was used to evaluate the
significant difference between control and test samples in flow
cytometry analysis. For comparison of the statistical differences
of more than two groups, one-way ANOVA and Newman-
Keul’s multiple comparison test was used. All other statistical
significant difference analyses were evaluated using Student’s t
test (Prism GraphPad, San Diego, CA). Statistical differences
between p22phox expression in benign and malignant pancre-
atic tissue groups on microarray were evaluated by Fisher’s
exact test. A p value of less than 0.05 was considered statistically
significant.
6SD. * p,0.05 (n= 3). (C) Increased protein level of p22phox in HPDE-K-rasG12V cells and primary pancreatic cancer cells Aspc1 and Panc-1 compared
to HPDE cells. (D) Increased NOX activity in the H-RASV12-transformed (T72Ras) cells compared to normal ovarian epithelial cells (T72). Error bars,6SD.
** p,0.01 (n=3). (E) Increased gene expression of NOX components (NOX1, NOX2, NOXA1, p22phox, and p47phox) in the H-RASV12-transformed
T72Ras cells when compared to the parental T72 cells. Expression of mRNA was measured by qRT-PCR analysis. Error bars, 6SD. * p,0.05; ** p,0.01
(n=3). (F) Preferential disruption of mitochondrial transmembrane potential by DPI (3–10 mM, 20 h) in H-RASV12-transformed T72Ras cells compared
with the parental T72 cells. Mitochondrial transmembrane potential was measured by flow cytometry using rhodamine-123 as a probe. (G)
Representative tissue staining showing no expression of p22phox protein in normal pancreas (a, single arrow, normal pancreatic duct; double arrows,
islet cells) and chronic pancreatitis (b, arrows, benign pancreatic ducts), and a moderately differentiated pancreatic ductal carcinoma (c) and strong
positive staining in a moderately differentiated pancreatic ductal carcinoma (d). The strong positive staining in the inflammatory cells served as
internal positive controls for our immunohistochemical stain (original magnification, 2006). Expression of p22phox in stage II pancreatic ductal
carcinoma (PDC) and benign pancreatic tissue on microarray. p22phox expression is considered to be significantly different between PDC and benign
group and higher in PDC group (p,0.0001 analyzed by Fisher’s exact test).
doi:10.1371/journal.pbio.1001326.g007
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Supporting Information
Figure S1 Figure S1 is related to Figure 4. (A) Comparison of
mRNA expression of NOX family genes in Tet/off and Tet/on
(day 8) cells, measured by semi-quantitative RT-PCR analysis.
(B) Increase in NOXA1 and p47phox mRNA expression in the
Tet/on cells, measured by semi-quantitative RT-PCR at the
indicated time points after POLGdn expression. (C) Compar-
ison of cell proliferation and morphology in cells with or without
mitochondrial defect induced by POLGdn (Tet/on or Tet/off
cells) treated with the NOX inhibitor DPI. The POLGdn-
inducible T-Rex 293 cells were pre-incubated with or without
doxycycline for 8 d and then treated with the indicated
concentrations of DPI for 24 h. Cell density (as an indication
of proliferation) and morphology were examined under a
microscope.
(TIF)
Figure S2 Figure S2 is related to Figure 5. (A–B) siRNA
knockdown of the NOX1 and p22phox in Tet/off or Tet/on cells
(at day 4), respectively. Cells were transfected with siRNAs against
NOX1, p22phox, or scramble RNA (SC) for 96 h. Knockdown
efficiency was evaluated by qRT-PCR. (C–D) Mass spectrometry
confirmation of NADH and NAD+ peaks from HPLC analysis.
(C) Identification of NADH eluted at 15–15.5 min from SAX
column in multiple salt forms. (D) Identification of NAD+
corresponding to the NAD+ peak eluted at 8.5–9.0 min. (E–G)
Detection of cellular O2
2, mitochondrial O2
2, and cellular H2O2
in p22phox siRNA transfected Tet/on (d4) cells. Tet/off cells were
used as control.
(TIF)
Figure S3 Figure S3 is related to Figure 6. (A) Increased
expression of NOX components NOX1, NOX5, and p67phox
in HCT116 p532/2 cells detected by semi-quantitative RT-
PCR assay. (B) HCT116 p532/2 and HCT116 p53+/+ cells
were seeded in six-well plates. Cells were cultured to
subconfluent and then treated with 30 mM DPI for 42 h
followed by annexin-V/PI double staining and flow cytometer
analysis. The number in each panel indicates percentage of
death cells. (C) H1299 cells were stably transfected with p53wt-
pcDNA3.1/zeocin plasmid. p53wt expression in H1299 was
confirmed by Western blot using anti-p53 antibody. (D)
Comparison of membrane-associated NOX activity in H1299
cells and p53wt stably transfected H1299 cells (H1299-p53wt).
Error bars, 6SD. *** p,0.001 (n= 3).
(TIF)
Figure S4 Figure S4 is related to Figure 7. (A) Real-time PCR
revealed that mRNA expression of NOX2 and NOXA1 were
upregulated after induction of K-Ras in T-Rex 293 cells. (B)
NOX2 and NOXA1 expression were also upregulated in K-ras
transformed pancreatic ductal epithelial cells (HPDE). Data are
shown as mean 6 SD of triplicate samples from two independent
experiments. p,0.0001 compared to cells without K-ras induc-
tion. (C) Increased expression of NOX components NOX1,
NOX2, p22phox, NOXA1, and p47phox in T72Ras cells detected
by semi-quantitative RT-PCR assay.
(TIF)
Figure S5 Figure S5 is related to Figure 8. Ten 9-wk-old nude
mice were inoculated subcutaneously with Panc-1 cells (56106/
0.15 ml/mouse) and randomly divided into two groups (five mice
each). After tumor formation (about 100 mm3), the treatment
group received DPI (1.5 mg/kg mouse, i.p.) 5 times per week. The
control group received an equal volume of PBS control. The mice
were monitored for tumor growth and body weight throughout the
experiment. (A) The body weights of the nude mice were
measured during the drug treatment to estimate toxicity. Error
bars, 6SEM (n=5). (B) The tumor sizes were measured
throughout the experiment to evaluate DPI effect. Data represent
tumor volume: mm36SEM (n=5). (C) Photographs of nude mice
bearing Panc-1 xenografts on day 65 of DPI treatment (one mouse
from each group was sacrificed 2 d before). PBS treatment was
used as control. (D) Tumor weight derived from control and DPI
treated mice on day 65 after DPI treatment was measured. Error
bars, 6SEM. p,0.01 and n=5.
(TIF)
Text S1 Supplemental materials and methods and supplemental
references.
(DOC)
Acknowledgments
The authors thank MitoKor, Inc. (San Diego, California) for providing the
plasmid containing POLGdn.
Author Contributions
The author(s) have made the following declarations about their
contributions: Conceived and designed the experiments:WL PH . Performed
the experiments: WL YH GC ZC HZ FW LF HP HW HW YL. Analyzed
the data: WL YH GC HW HW YL. Contributed reagents/materials/
analysis tools: WL JL MK WM YL. Wrote the paper: HP WL YH.
Figure 8. Inhibition of pancreatic tumor growth by NOX inhibition. (A) Decrease of NOX activity by stable shRNA knockdown of
p22phox (p22phox-shRNA) in Panc-1 cells, but not in cells with control shRNA (c-shRNA) knockdown. *** p,0.001 (n = 3). Insert, Panc-1 cells
were infected with p22phox-shRNA lentiviral particles, and the knockdown efficiency was detected by anti-p22phox antibody using Western
blot. Non-targeting control shRNA lentiviral particles (c-shRNA) were used as negative control. (B) p22phox knockdown significantly decreased
Panc-1 cell growth. 16105 cells were seed to six-well plates. Cell numbers were counted using Z2 coulter counter (Beckman Coulter) during 6 d
of culture. (C) p22phox knockdown significantly suppressed colony formation of Panc-1 cells. 16104 cells were seed in 0.35% of the soft agar
and assayed for colony formation after 2 wk. The numbers of colonies formed on soft agar were counted. Error bars, 6SD. *** p,0.001 (n = 3).
(D) p22phox knockdown decreased glucose uptake in Panc-1 cells. Cells (16106) were incubated in 5 ml glucose-free DMEM medium for 4 h,
followed by incubation with 0.2 mCi/mL 3H-2-deoxyglucose for 1 h. Cellular uptake of 3H-2-deoxyglucose was determined by liquid scintillation
counting after the cells were washed 2 times with PBS and normalized by cell number. Error bars, 6SD. * p,0.05 (n = 3). (E) p22phox
knockdown decreased lactate generation in Panc-1 cells. Lactate was measured 24 h after changing to fresh culture medium and normalized
by cell number. Error bars, 6SD. ** p,0.01 (n = 3). (F–I) Each side of athymic nude mice (n = 7) received subcutaneously injections of 56106
Panc-1 cells bearing p22phox-shRNA (left flank) or c-shRNA (right flank). The mice were monitored for tumor growth and body weight
throughout the experiment. All the mice were sacrificed when tumor size reached about 10% of body weight as mandated by the IACUC
protocol. Tumor volume was calculated using the following equation: tumor volume (mm3) = L * W *(L+W)/2 * 0.526. (F) The tumor sizes were
measured throughout the experiment to evaluate p22phox knockdown effect. Data represent tumor volume: mm36SEM. *** p,0.001 (n = 7).
(G) Photographs of athymic nude mice bearing p22phox-shRNA (left flank) or c-shRNA (right flank) xenografts. (H) Photograph and comparison
of excised tumor size. (I) Tumor weight derived from p22phox-shRNA knockdown or c-shRNA knockdown was measured. Error bars, 6SEM.
p,0.05 (n = 7).
doi:10.1371/journal.pbio.1001326.g008
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